Koronare Herzkrankheit: Aktueller Stand der klinischen Anwendung der Myokardperfusionsszintigrafie im Rahmen des chronischen Koronarsyndroms

Zusammenfassung

Die Myokardperfusionsszintigrafie (MPS) hat sich im Bereich der klinischen Anwendung und Methodik in Deutschland in den 10 letzten Jahren kontinuierlich entwickelt. Die neue europäische Leitlinie zur Diagnostik und Behandlung des neu definierten chronischen Koronarsyndroms hat die Rolle der nicht invasiven Bildgebung und damit der nuklearmedizinischen Verfahren bestätigt und gestärkt. Die MPS liefert wertvolle Beiträge zur klinischen Prognoseeinschätzung und Therapieentscheidung aufgrund des Zusammenhanges von szintigrafisch nachgewiesener Perfusionsstörung mit der Häufigkeit von kardiovaskulärem Tod und nicht tödlichem Herzinfarkt.

In diesem Artikel wird ein Überblick über die Einsatzbereiche, die aktuellen Leitlinien und den momentanen Stellenwert der MPS sowie eine kurze Zusammenfassung der praktischen Anwendung des Verfahrens gegeben.

Abstract

Myocardial perfusion scintigraphy (MPS) has been continuously developing in the field of clinical applications and methodology in Germany within the last 10 years. The new European guidelines for the diagnosis and treatment of the newly defined chronic coronary syndrome has confirmed and strengthened the role of non-invasive imaging and thus of nuclear medicine procedures.

MPS provides valuable contributions to the clinical prognosis assessment and treatment decision due to the established relationship between proven regional ischemia and the incidence of cardiovascular death and non-fatal myocardial infarction.

Tis article gives an overview of the application fields, of the current guidelines and of the current clinical status of the MPS, as well as a brief summary of the practical application of the procedure.

Schlüsselwörter

Nuklearkardiologie - Myokard-Perfusions-Szintigrafie - koronare Herzkrankheit

Keywords

nuclear cardiology - myocardial perfusion scintigraphy - coronary heart

• Literatur

• 1 Fox KAA, Metra M, Morais J. et al. The myth of ‘stable’ coronary artery disease. Nat Rev Cardiol 2019; [im Druck]
• 2 Knuuti J, Wijns W, Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019; [im Druck]
• 3 Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003
• 4 Lindner O, Bengel F, Burchert W. et al. Myokard-Perfusions-SPECT (DGN Handlungsempfehlung (S1-Leitlinie)). 2017 (AWMF Registernummer 031-006)
• 5 Bundesärztekammer. Kassenärztliche Bundesvereinigung. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale Versorgungs-Leitlinie Chronische KHK (Langfassung), 5. Auflage 2019 Version 1 (AWMF-Register-Nr.: nvl-004).
• 6 Lindner O, Bauersachs J, Bengel F. et al. Positionspapier Nuklearkardiologie - Update 2018. Aktueller Stand der klinischen Anwendung. Nuklearmedizin 2018; 57: 146-152
• 7 Greenwood JP, Ripley DP, Berry C. et al. Effect of care guided by cardiovascularmagnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the CE-MARC 2 randomized clinical trial. JAMA 2016; 316: 1051-1060
• 8 Knuuti J, Ballo H, Juarez-Orozco LE. et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J 2018; 39: 3322-3330
• 9 Lindner O, Burchert W, Schäfer WM. et al. Myocardial Perfusion SPECT 2018 in Germany: Results of the 8th Survey. Nuklearmedizin 2019; 58: 425-433
• 10 Hachamovitch R, Hayes SW, Friedman JD. et al. Comparison of the short-term survivalbenefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107: 2900-2907
• 11 Shaw LJ, Berman DS, Maron DJ. et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117: 1283-1291
• 12 Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2014; 35: 2541-2619
• 13 Schinkel AF, Bax JJ, Poldermans D. et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007; 32: 375-410
• 14 Bonow RO, Maurer G, Lee KL. et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011; 364: 1617-1625
• 15 McMurray JJ, Adamopoulos S, Anker SD. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012; 14: 803-869
• 16 Carson P, Wertheimer J, Miller A. et al. Surgical Treatment for Ischemic Heart Failure (STICH) Trial: Mode of Death Results. JACC Heart Fail 2013; 1: 400-408
• 17 Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 2015; 22: 229-245
• 18 Van Dongen AJ, van Rijk PP. Minimizing liver, bowel, and gastric activity in myocardial perfusion SPECT. J Nucl Med 2000; 41: 1315-1317
• 19 Verberne HJ, Acampa W, Anagnostopoulos C. et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging 2015; 42: 1929-1940
• 20 Zoghbi GJ, Dorfman TA, Iskandrian AE. The effects of medications on myocardial perfusion. J Am Coll Cardiol 2008; 52: 401-416
• 21 Yoon AJ, Melduni RM, Duncan SA. et al. The effect of beta-blockers on the diagnostic accuracy of vasodilator pharmacologic SPECT myocardial perfusion imaging. J Nucl Cardiol 2009; 16: 358-367
• 22 Reyes E, Stirrup J, Roughton M. et al. Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study. J Nucl Med 2010; 51: 1036-1043
• 23 Hoffmeister C, Preuss R, Weise R. et al. The effect of beta blocker withdrawal on adenosine myocardial perfusion imaging. J Nucl Cardiol 2014; 21: 1223-1229
• 24 Smits P, Lenders JW, Thien T. Caffeine and theophylline attenuate adenosine induced vasodilation in humans. Clin Pharmacol Ther 1990; 48: 410-418
• 25 Bottcher M, Czernin J, Sun KT. et al. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation. J Nucl Med 1995; 36: 2016-2021
• 26 Hesse B, Tagil K, Cuocolo A. et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005; 32: 855-897
• 27 Knuuti J, Bengel F, Bax JJ. et al. Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease. Eur Heart J 2014; 35: 633-638
• 28 Bundesamt für Strahlenschutz. Bekanntmachung der aktualisierten diagnostischen Referenzwerte für nuklearmedizinische Untersuchungen vom 25. September 2012. BAnz AT 19.10.2012 B5.
• 29 Hyafil F, Gimelli A, Slart RHJA. et al. EANM procedural guidelines for myocardial perfusion scintigraphy using cardiac-centered gamma cameras. European J Hybrid Imaging 2019; 3: 11
• 30 Einstein AJ, Blankstein R, Andrews H. et al. Comparison of image quality, myocardial perfusion, and left ventricular function between standard imaging and single-injection ultra-lowdose imaging using a high-efficiency SPECT camera: the MILLISIEVERT study. J Nucl Med 2014; 55: 1430-1437
• 31 Songy B, Guernou M, Hivoux D. et al. Prognostic value of one millisievert exercise myocardial perfusion imaging in patients without known coronary artery disease. J Nucl Cardiol 2018; 25: 120-130
• 32 Giorgetti A, Rossi M, Stanislao M. et al. Feasibility and diagnostic accuracy of a gated SPECT early imaging protocol: a multicenter study of the Myoview Imaging Optimization Group. J Nucl Med 2007; 48: 1670-1675
• 33 Hara M, Monzen H, Futai R. et al. Reduction of infracardiac intestinal activity by a small amount of soda water in technetium-99m tetrofosmin myocardial perfusion scintigraphy with adenosine stress. J Nucl Cardiol 2008; 15: 241-245
• 34 Druz RS, Akinboboye OA, Grimson R. et al. Postischemic stunning after adenosine vasodilator stress. J Nucl Cardiol 2004; 11: 534-541
• 35 Hachamovitch R, Rozanski A, Hayes SW. et al. Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary?. J Nucl Cardiol 2006; 13: 768-778
• 36 Hendel RC, Corbett JR, Cullom SJ. et al. The value and practice of attenuation correction for myocardial perfusion SPECT imaging: a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine. J Nucl Cardiol 2002; 9: 135-143
• 37 Preuss R, Weise R, Lindner O. et al. Optimisation of protocol for low dose CT derived attenuation correction in myocardial perfusion SPECT imaging. Eur J Nucl Med Mol Imaging 2008; 35: 1133-1141
• 38 Sharir T, Bacher-Stier C, Dhar S. et al. Identification of severe and extensive coronary artery disease by post exercise regional wall motion abnormalities in Tc-99m sestamibi gated single-photon emission computed tomography. Am J Cardiol 2000; 86: 1171-1175
• 39 Hachamovitch R, Berman DS, Shaw LJ. et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998; 97: 535-543